Peptides for Weight Loss: What the Metabolic Research Actually Shows

GLP-1 is a gut hormone that stimulates insulin secretion, inhibits glucagon secretion, slows gastrointestinal motility and appears to be a physiological regulator of appetite and food intake. Native GLP-1 is inactivated very rapidly by the enzyme DPP-IV, so the peptides used in weight-management trials are modified analogues given once weekly.^[6][1]

The trial programmes are large. In STEP 1, 1,961 adults without diabetes lost a mean 14.9% of body weight over 68 weeks on weekly semaglutide, against 2.4% with placebo. In SURMOUNT-1, 2,539 adults lost 15.0% to 20.9% over 72 weeks on tirzepatide, against 3.1%. SELECT, with 17,604 participants who had cardiovascular disease and overweight or obesity, found a lower risk of major cardiovascular events with semaglutide (hazard ratio 0.80).^[1][2][3]

That depth is why both molecules are authorised medicines in the EU for weight management, as Wegovy and Mounjaro, used alongside diet and physical activity. Those authorisations cover specific pharmaceutical products with approved labels, not research compounds that share the same name.^[15][16]

Gastrointestinal effects dominate. In STEP 1, nausea and diarrhoea were the most common adverse events with semaglutide, typically transient and mild to moderate, and 4.5% of participants stopped treatment because of gastrointestinal events, against 0.8% on placebo. In SURMOUNT-1, gastrointestinal events were also the most common, occurring mainly during dose escalation, and 4.3% to 7.1% of participants on tirzepatide discontinued because of adverse events, against 2.6% on placebo.^[1][2]

Longer exposure changes the picture. In SELECT, where the mean exposure was about 34 months, adverse events led to permanent discontinuation in 16.6% of participants on semaglutide, against 8.2% on placebo. Discontinuation figures from shorter trials should be read with their duration in mind.^[3]

The withdrawal data are among the most important and least quoted results in this field. In the STEP 1 extension, participants who stopped semaglutide and the lifestyle programme regained two-thirds of their prior weight loss within a year, and most cardiometabolic improvements reverted towards baseline.^[4]

SURMOUNT-4 tested the same question as a randomised withdrawal trial. After a 36-week tirzepatide lead-in, participants switched to placebo regained 14.0% of body weight over the next 52 weeks, while those who continued treatment lost a further 5.5%.^[5]

Both trial teams reached the same conclusion: in these studies the effect lasted only as long as the treatment, which is consistent with obesity behaving as a chronic condition rather than one that a fixed course resolves.^[4][5]

Retatrutide adds a glucagon-receptor arm to GIP and GLP-1 agonism. Its 48-week phase 2 obesity trial in 338 adults reported mean weight reductions of up to 24.2%, against 2.1% with placebo, with dose-related gastrointestinal effects and a dose-dependent rise in heart rate.^[7]

Mazdutide and survodutide pair GLP-1 with glucagon agonism. In GLORY-1, Chinese adults lost 11.00% and 14.01% of body weight at 48 weeks on two mazdutide doses; in SYNCHRONIZE-1, adults with obesity lost 12.2% and 13.0% at 76 weeks on survodutide, against 5.4% with placebo.^[8][9]

A 2026 BMJ network meta-analysis of 262 trials puts these figures in proportion. It found that emerging agents such as mazdutide and retatrutide may produce weight reductions similar to or greater than established drugs, but with very low to low certainty, and that larger benefits generally came with more harms and discontinuations.^[13]

Tesamorelin is a growth-hormone-releasing factor analogue. In a 26-week randomised trial of 412 people with HIV and abdominal fat accumulation, visceral adipose tissue fell by 15.2% on daily tesamorelin and rose by 5.0% on placebo, while IGF-1 levels rose by 81%. The finding concerns visceral fat in that population, not general weight loss.^[10]

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In mice it acted mainly on skeletal muscle, activated the energy sensor AMPK and prevented diet-induced obesity and insulin resistance. A placebo-controlled phase 2a trial in adults with prediabetes and overweight or obesity began recruiting in 2026, with insulin sensitivity as its primary outcome; until trials like it report, the metabolic case for MOTS-c rests largely on animal data.^[11][12]

Three questions separate evidence from marketing. What phase and size is the trial behind the claim? Which population was studied? And what happened to lean mass, side effects and weight after stopping? In the 2026 BMJ network meta-analysis, tirzepatide reduced fat mass the most (by 25.7%) but also lean mass the most (by 8.3%), and most agents did not improve quality of life meaningfully.^[13]

Products sold outside medical channels add another layer of uncertainty. A 2026 review warned that unregulated injectable peptides, including investigational agents such as retatrutide, lack established human safety profiles and carry risks of contamination, manufacturing impurities and inaccurate dosing.^[14]

Peptyds supplies research peptides for in-vitro laboratory work only, with batch documentation described on the quality page. None is a weight-loss product, and nothing on this page is a recommendation for personal use.